The proposal would expand coverage of anti-obesity drugs to 7.5 million people covered by Medicare and Medicaid, the Biden administration said.

President Joe Biden’s proposal to have GLP-1 weight-loss drugs such as Ozempic and Mounjaro covered by Medicare and Medicaid would help tackle the public-health crisis of obesity, but it would raise the costs for the government programs by billions of dollars per year.